Form 10 Explorer
10-Q
Quarterly Report
AIM IMMUNOTECH INC.

AIM

NYSEAMER

CIK: 946644

File #: 001-27072

Period End: Jun 30, 2026

Fiscal Year: 2026

View on EDGAR
Balance Sheet
40 line items · 2 periods
XBRL
ItemJun 30, 2026Dec 31, 2025
ASSETS
Current assets:
Cash and Cash Equivalents
9,900,0002,985,000
Marketable securities
64,00062,000
Fair Value, Recurring
64,00062,000
Fair Value, Inputs, Level 1 - Fair Value, Recurring
64,00062,000
Accounts Receivable
7,000
Other Non-Operating Current Assets
468,000241,000
Total current assets
10,432,0003,295,000
Property, Plant and Equipment
54,00071,000
Operating Lease Right-of-Use Asset
260,000378,000
Intangible Assets
1,714,0001,661,000
Patents
1,657,0001,599,000
Trademarks
57,00062,000
Other Non-Operating Non-Current Assets
271,000377,000
Total assets
12,731,0005,782,000
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)
Current liabilities:
Accounts Payable
480,0001,630,000
Other Current Liabilities
586,000795,000
Operating Lease Liability, Current
259,000250,000
Short-Term Debt
3,621,0003,549,000
Total current liabilities
4,946,0006,224,000
Long-term liabilities:
Operating Lease Liability, Non-Current
41,000170,000
Long-Term Debt
927,000
Other Non-Operating Non-Current Liabilities
8,244,000
Fair Value, Recurring
8,244,000
Fair Value, Inputs, Level 3 - Fair Value, Recurring
8,244,000
Total liabilities
4,987,00015,565,000
Stockholders’ equity (deficit):
Total Stockholders' Equity
29,0003,000
Total Stockholders' Equity
455,312,000431,000,000
Total Stockholders' Equity
(447,597,000)(440,786,000)
Total stockholders’ equity (deficit)
7,744,000(9,783,000)
Series G Preferred Stock - Preferred Stock
529,000
Common Stock
29,0003,000
Additional Paid-in Capital
455,312,000431,000,000
Retained Earnings
(447,597,000)(440,786,000)
Total liabilities and stockholders’ equity
12,731,0005,782,000